Skip to Main Content

AbbVie, Inc. Securities Fraud Class Action

View Complaint
COMPANY         AbbVie, Inc.
COURT United States District Court for the Northern District of Illinois
CASE NUMBER 22-cv-01773
JUDGE The Honorable Harry Daniel Leinenweber
CLASS PERIOD April 30, 2021 - August 31, 2021

Case Background:

On April 6, 2022, an initial complaint was filed against AbbVie, Inc. (“AbbVie” or the “Company”) and certain of AbbVie’s directors and officers, asserting violations of Sections 10(b) and 20(a) of the Securities Exchange Act.   The class action lawsuit was filed on behalf of those who purchased or acquired AbbVie securities between April 30, 2021 and August 31, 2021, inclusive (the “Class Period”).

The complaint alleges that, throughout the Class Period, the Defendants made materially false and/or misleading statements, about the company’s business and operations.  Specifically, Defendants misrepresented and/or failed to disclose that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, Defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis, As a result of the Defendants’ wrongful acts and omissions, and the significant decline in the market value of AbbVie’s securities, AbbVie investors have suffered significant damages.

Current Status of Case:

This action was voluntarily dismissed on February 16, 2023. This action has concluded. 

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP:  Jon Naji, Esq. (484) 270-1453 or via e-mail at  

* Denotes required field
# of Shares
Price per Share
Principal Amount
Amount Paid
Series or CUSIP
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of AbbVie, Inc. prior to the Class Period?
Are you a current or former employee of AbbVie, Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email